Cartesian Therapeutics (RNAC) Short-Term Debt issuances (2017)

Cartesian Therapeutics' (RNAC) quarterly Short-Term Debt issuances came in at -$42000.0 in Q4 2017.

Cartesian Therapeutics (RNAC) Short-Term Debt issuances (2017) Analysis & Trends

Cartesian Therapeutics (RNAC) has 1 years of Short-Term Debt issuances data on file, last reported at -$42000.0 in Q4 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 58.20 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Cartesian Therapeutics 226.07 Mn 226.07 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2017 -42,000.00
Dec 31, 2017 -42,000.00